Investors / United States / Omega Funds
Omega Funds
Venture capital · Boston, MA, United States · North America
Omega Funds invests in founders and companies developing products and platforms in medicine, and states it has helped bring 56 products to patients. It operates from offices in Boston and Geneva and manages a series of numbered funds.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsoncologyimmunologyrare diseasesprecision medicine
Your fit with Omega Funds
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsOmega Funds lists 87 checked portfolio companies on its own site and is named in 10 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 60% of the companies with a known first round. Its largest themes are Healthcare & Biotech (84%), Fintech (2%) and AI & Machine Learning (2%). 65% of its companies are based in United States. It invests most often alongside RA Capital, Atlas Venture and Jeito Capital.
Counts come from funding rounds that name Omega Funds, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Omega Funds' whole history. Rounds on record name 10 companies; its own site lists 87. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundOmega Funds does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 40% |
| Series B | 60% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 3 | 0 |
| '26 | 7 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 94th | 86 companies |
| Recent activity | 93th | 8 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 75th | 9% of companies confirmed by a round |
| Sector focus | 94th | 84% in its largest sector |
| Reach | 97th | 12 countries |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 84% | 15% |
| Fintech | 2% | 12% |
| AI & Machine Learning | 2% | 18% |
| Media & Entertainment | 2% | 4% |
| Industrial & Manufacturing | 2% | 7% |
| Education | 1% | 7% |
| Enterprise Software | 1% | 8% |
| E-commerce & Marketplaces | 1% | 6% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 7 |
| Atlas Venture | 6 |
| Jeito Capital | 6 |
| ARCH Venture Partners | 5 |
| Aisling Capital | 5 |
| Frazier Life Sciences | 5 |
| NEA | 5 |
| Foresite Capital | 4 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers7890%
- No longer answers00%
- Points to another company910%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherCompare Omega Funds head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Omega Funds| Date | Company | Stage |
|---|---|---|
| 11 Aug 2026 | Series B | |
| 4 May 2026 | Series B | |
| 4 Feb 2026 | Series A | |
| 14 Jan 2026 | Series A | |
| 8 Jan 2026 | Series A | |
| 7 Jan 2026 | Series A | |
| 1 Dec 2025 | Series B | |
| 8 Sept 2025 | Series B |
Round details for Omega Funds
Amounts, full round histories and every co-investor in Omega Funds' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
87 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Acrux develops and commercialises a pipeline of topically applied pharmaceutical products. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Alleviant Medical is currently evaluating interatrial shunt therapy in heart failure patients through clinical trials. | Healthcare & Biotech | Portfolio page | ||
FintechAI & Machine Learning | Portfolio page | |||
| Alumis Inc is focused on immune-mediated disease therapies | Healthcare & Biotech | Portfolio page | ||
| Alveus Therapeutics develops treatments for obesity and weight loss maintenance | Healthcare & Biotech | Jan 2026Series A | Page + round | |
| Aquarius designs and supplies aeration systems for wastewater treatment | Industrial & ManufacturingEnterprise Software | Portfolio page | ||
| Arcutis Biotherapeutics develops targeted therapies for chronic immune-driven skin diseases. | Healthcare & Biotech | Portfolio page | ||
| Arrakis Therapeutics creates genetic medicines, specifically RNA-targeted small molecules, to treat various diseases. | Healthcare & Biotech | Portfolio page | ||
| ARTBIO develops alpha radioligand therapies for cancer treatment. | Healthcare & Biotech | Jul 2025Series B | Funding round | |
| Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases. | Healthcare & Biotech | Portfolio page | ||
| Aviceda Therapeutics develops novel therapies to improve the lives of patients with immune-mediated diseases | Healthcare & Biotech | Portfolio page | ||
| Beam Therapeutics is a company that develops precision genetic medicines using base editing technology | Healthcare & Biotech | Portfolio page | ||
| Beta Bionics develops an insulin delivery system that automatically learns and adapts to a user's needs | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| The company aims to inhibit the active ON state of RAS signaling in cancer, using expert understanding of RAS signaling biology to inform rational drug design. | Healthcare & Biotech | Portfolio page | ||
| Caldera Therapeutics is a clinical-stage biotechnology company developing a potential first-in-class bispecific antibody for inflammatory bowel disease and other immune-mediated diseases. | Healthcare & Biotech | Jan 2026Series A | Page + round | |
| Callio Therapeutics is a global, clinical-stage biotechnology company developing dual-payload antibody-drug conjugates (ADCs) to address the key limitation of current therapies, resistance. | Healthcare & Biotech | Portfolio page | ||
| CatalYm is developing a safe and efficacious immune therapy for solid tumors. | Healthcare & Biotech | Portfolio page | ||
| CDR-Life develops innovative treatments for cancer and autoimmune diseases through its T cell engager platform, M-gager | Healthcare & Biotech | Portfolio page |
About this data
site last read 11 Nov 2026- Site
- omegafunds.com
- Last read
- 11 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 29 Jul 2025
- Companies checked
- 87
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Omega Funds' profile as data
Pull Omega Funds' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/omegafunds.com
# also
GET /v1/firms/omegafunds.com/portfolio
GET /v1/firms/omegafunds.com/coinvestors
GET /v1/firms/omegafunds.com/news